Orphazyme prepares for USD 50m capital hunt after nightmare year

After a year that brought Orphazyme failed studies and a rejection from the FDA, the Copenhagen-based biotech firm is now planning to bring in USD 50m by issuing American Depositary Shares (ADSs).
Photo: Orphazyme/PR
Photo: Orphazyme/PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

Biotech business Orphazyme, which is based in Copenhagen, Denmark, is planning to raise USD 50m through an American Depositary Shares (ADSs) issuance, it reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading